Kintor Pharmaceutical's revenue per share for the
six
months ended in Dec. 2024 was HK$0.01.
Kintor Pharmaceutical's revenue per share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.01.
Warning Sign:
Kintor Pharmaceutical Ltd revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue Per Share Growth Rate was -53.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Kintor Pharmaceutical's Revenue per Share or its related term are showing as below:
HKSE:09939'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.3 Med: 118 Max: 289.3
Current: -53.3
During the past 7 years, Kintor Pharmaceutical's highest 3-Year average Revenue Per Share Growth Rate was 289.30% per year. The lowest was -53.30% per year. And the median was 118.00% per year.
HKSE:09939's 3-Year Revenue Growth Rate is ranked worse than 91.24% of 788
companies
in the Biotechnology industry
Industry Median: 0.5
vs HKSE:09939: -53.30
Kintor Pharmaceutical Revenue per Share Historical Data
The historical data trend for Kintor Pharmaceutical's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintor Pharmaceutical's Revenue per Share
For the Biotechnology subindustry, Kintor Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's PS Ratio falls into.
Kintor Pharmaceutical Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Kintor Pharmaceutical's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (HKSE:09939) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Kintor Pharmaceutical Revenue per Share Related Terms
Thank you for viewing the detailed overview of Kintor Pharmaceutical's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09939 has been successfully added to your 